Latest Stimulants Stories
SOUTH SAN FRANCISCO, Calif., Jan.
KP415 is Designed as an Abuse-Deterrent, Controlled Release Prodrug of Methylphenidate for the Treatment of ADHD CORALVILLE, Iowa, Dec.
- Patent for naltrexone SR formulation expected to extend Contrave protection to 2028 SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc.
TORONTO, Nov. 20, 2014 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"), a pharmaceutical company, today announced that the U.S.
- Study successfully meets primary endpoint- Lack of sleep-related side effects supports flexible nighttime dosing platform to target control over symptoms during the morning routine-
PHILADELPHIA, October 9, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has received further guidance from the U.S.
TORONTO, Oct. 6, 2014 /PRNewswire/ - Highland Therapeutics Inc.
18-MC Well Tolerated by Subjects in Development Partner's Study SAN CARLOS, Calif., Oct.
18-MC Well Tolerated by Subjects in Development Partner's Study SAN CARLOS, Calif., Sept.
WOODCLIFF LAKE, N.J. and SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc.
- totally perplexed and mixed up.